Antitrypsin Deficiency Liver Disease

Gastroenterology
1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Alnylam Pharmaceuticals
1 program
1
ALN-AATPhase 11 trial
Active Trials
NCT02503683Terminated26Est. Jan 2018

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alnylam PharmaceuticalsALN-AAT

Clinical Trials (1)

Total enrollment: 26 patients across 1 trials

A Study of an Investigational Drug, ALN-AAT, in Healthy Adult Subjects and Patients With ZZ Type Alpha-1 Antitrypsin Deficiency Liver Disease

Start: Jul 2015Est. completion: Jan 201826 patients
Phase 1Terminated

Related Jobs in Gastroenterology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space